INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 that is SARS-CoV-2 has become a pandemic and people are confronting it. It appears that the coronavirus has been in multiple countries and billions of people. There is wide variability in the anti-pneumococcal antibody response of normal subjects as shown in one study. Anti-capsular polysaccharide antibodies are believed to represent the single most important protective mechanism against invasive disease. The basis of serum therapy was antibodies to pneumococcal polysaccharides in which passively transferred, serotype-specific anti-pneumococcal serum has reduced mortality from pneumococcal pneumonia by making it into half. The example of antibody-polysaccharide antigens includes pneumococcal vaccine.

Streptococcus pneumoniae has capsular polysaccharide and shows a diverse group of polymers. A previous study demonstrated the virulence of bacterium and its essential role with 90 serologically distinct capsules. Vaccination of infants and young children with the pneumococcal conjugate vaccine has decreased in nasal carriage rates and pneumococcal disease in all age groups. Antibodies to capsular polysaccharide antigens provide serotype-specific protection against serious infections such as pneumonia, and the pneumococcal vaccines are designed to cover the serotypes most commonly associated with severe pneumococcal disease. Currently, a pneumococcal polysaccharide vaccine has a total of 23 serotypes that are 23-valent and a 7-valent polysaccharide-protein conjugate vaccine has been marketed internationally. Both vaccines are considered very safe. Respiratory secretions from the patient and direct contact with the healthy person pneumococci are getting transmitted. There are serious pneumococcal infections such as pneumonia, meningitis, and febrile bacteremia, and other respiratory disorders that are more common but have less serious manifestations.

The previous study demonstrated that pneumonia is a leading cause of community-acquired pneumonia irrespective of comorbidity, individuals with chronic lung diseases, particu-
larly those with COPD, are at increased risk of pneumococcal community-acquired pneumonia and invasive pneumococcal disease, are prone to higher rates of complications and mortality and suffer prolonged recovery after such illnesses. One study shows acute pulmonary embolism and Chest CT plays an important role in the management of patients with COVID-19. The symptoms of coronavirus are similar to influenza that is fever, cough, sore throat, and also major respiratory problems that are a problem in breathing and highly prevalent shown in one study. COVID-19 does not cause Nocturia. Diabetic people can be a risk factor of COVID-19. Generally, coronaviruses were not considered to be highly pathogenic to humans until the outbreak of Severe Acute Respiratory Syndrome (SARS) in 2002 and 2003. Hysterectomy can be risky during COVID-19. It alters the hemoglobin level. Lung cancer patients have higher chances of SARS. To understand how vaccination can stop a disease spreading through an otherwise susceptible population it can be done by game-based learning methods. Vitamins help in fighting COVID-19.

This review of the literature has been done by collecting and retrieving information for a minimum of 30 articles. Articles were selected from Pubmed, google scholar, etc.

COVID-19 AND ANTI-PNEUMOCOCCAL ANTIBODY

COVID-19 Pneumonia

COVID-19 pneumonia is a specific disease with hypoxemia and is also associated with normal respiratory compliance. Hypoxicemic patients have the same single etiology (SARS-CoV-2) but show different symptoms from others like normal breathing (“silent” hypoxemia) or remarkably dyspneic; quite responsive to nitric oxide or not.

A previous study demonstrated the beginning of COVID-19 Pneumonia having characteristics of Low elastance which estimates that the amount of gas in the lung is nearly normal. Low ventilation-to-perfusion, low lung weight, and low lung recruit ability, the amount of non-aerated tissue are very low; consequently, the recruiting ability is low. These are L-type COVID-19 Pneumonia. H-type COVID-19 Pneumonia has characteristics of High elastance that is the decrease in gas volume due to increased edema accounts for the increased lung elastance, High right-to-left shunt. Due to increased edema and superimposed pressure in the dependent lung regions, it will be developed by the fraction of cardiac output perfusing the non-aerated tissue. High lung weight that is quantitative analysis of the CT scan shows a remarkable increase in lung weight (>1.5 kg), on the order of magnitude of severe ARDS. High lung recruit ability that is an increased amount of non-aerated tissue is associated, as in severe ARDS, with increased recruit ability.

The Type H pattern, 20–30% of patients in our series, fully fit the severe ARDS criteria: hypoxemia, bilateral infiltrates, decreased respiratory system compliance, increased lung weight, and potential for recruitment. Type L and Type H patients are best identified by CT scan and are affected by different pathophysiological mechanisms. COVID-19 can alter hemoglobin level. Ankylosing spondylitis patients on biologics should take extra precautions to minimize the risk of contracting a COVID-19 infection. Cancer people should be more careful.

Anti-Pneumococcal Antibody

Streptococcus pneumoniae is an important human pathogen causing asymptomatic carriage as well as important mucosal and systemic infections. Anti-capsular antibodies are thought to represent the single most important protective mechanism against invasive disease. Antibodies to pneumococcal capsular polysaccharides were the basis of serum therapy in which passively transferred, serotype-specific anti-pneumococcal serum was shown to reduce mortality from pneumococcal pneumonia by half. Resistance to pneumococcal colonization is determined by the antibodies to the pathogen. Anti capsular antibodies reduce the pneumococcal colonization and protect nasopharyngeal carriage. The WHO has anticipated new modifications in antibody assays for pneumococcal anti-capsular antibodies which can be useful for the people. There is an outlined principle to determine to change the protective concentration of such assay modifications. For improvement of ELISA for anti-capsular antibodies this principle was applied, i.e. absorption with 22F pneumococcal polysaccharide, that increases the specificity of the assay for vaccine serotype anti-capsular antibodies by removing non-specific antibodies. Liquid Paraffin on Antibody Responses and Local Adverse Reactions of Bivalent Oil Adjuvanted Vaccines Containing Newcastle Disease Virus and Infectious Bronchitis Virus.

Detection of Specific Antibodies to SARS

One study reported the evaluation of recombinant severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) nucleocapsid protein enzyme-linked immunosorbent assay (ELISA)-based antibody tests for serodiagnosis of SARS-CoV pneumonia and compare the sensitivities and specificities of this ELISA for detection of immunoglobulin G (IgG), IgM, IgA, and their combinations with serum samples from healthy blood donors. The specificities of the ELISA for IgG, IgM, and IgA detection were higher respectively. The test for diagnosis of SARS-CoV pneumonia is sensitive which is done by ELISA and does not require the cultivation of SARS-CoV. Isolation of coronavirus is insensitive in clinical laboratories for diagnosis of SARS-CoV, while the detection of viral RNA by reverse transcription-PCR can achieve a sensitivity of only 50 to 79%, depending...
on the type and number of clinical specimens collected and the protocol used\textsuperscript{29,30}. During the SARS epidemic, using the ELISA test will be useful for the diagnosis of SARS-CoV pneumonia. It is well known that in the presence of possible cross-reactions, the positive predictive value of serological tests depends on the prevalence of the infection in a particular location at a particular moment. On the other hand, the positive predictive value of the serological test would be increased if the prevalence of the infection is high, such as during an epidemic and when applied in clinically compatible cases\textsuperscript{31}.

**Vaccine Development**

One study reported that the Polysaccharides that were identified coursing along the exterior of the bacterium could be targeted for vaccine development. British physician Sir Almroth Wright conducted the first large clinical trial of a whole-cell pneumococcal vaccine.

![Figure 1: (A): Pneumococcus bacteria and virulence factors including capsular polysaccharide, (B): Immune response to polysaccharide and protein-polysaccharide conjugate vaccines.](image)

For the next three decades, the trial for vaccine development was largely unsuccessful. Streptococcus pneumonia is a bacterium with 93 different polysaccharide capsular serotypes as shown in Figure 1A, the most important determinant of pneumococcal virulence is an antiphagocytic bacterial capsule. Immune response to polysaccharide and protein-polysaccharide conjugate vaccines in Figure 1B.

Polysaccharide pneumococcal vaccines have evolved over the past 20 years, using both unconjugated polysaccharides and polysaccharides conjugated to toxins to elicit a protective immune response in groups at risk for pneumococcal infection. Current CDC immunization guidelines for these vaccines have reduced the rates of pneumococcal infections within immunized communities\textsuperscript{33}. Vaccines against pneumonia, such as a pneumococcal vaccine, do protect against the COVID 19. The virus is new so it will take some time for the production of the vaccine against it. A pneumococcal vaccine is not enough for this virus. Scientists are trying to develop a vaccine against coronavirus as the pneumococcal vaccine is not enough.

One study reported that stem cells are unspecialized cells that have a property of differentiating into specific specialized cell types\textsuperscript{34}. Using umbilical cord mesenchymal stem cells, protection against coronavirus can be done in the future. As vaccination is important for everyone\textsuperscript{35}.

**Table 1: Advantages and disadvantages of 23-valent PS vaccine**

<table>
<thead>
<tr>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The vaccine covers a large number of serotypes</td>
<td>• Cannot be used on children &lt;2 years</td>
</tr>
<tr>
<td>• Serotypes covered account for 85-90% of invasive pneumococcal diseases in the US (ACIP, 1997)</td>
<td>• Cannot be used on immunodeficient patients</td>
</tr>
<tr>
<td>• It is cost effective and widely used in developing countries</td>
<td>• Time period of protection is limited because of no T-cell response (Bogaert, 2004).</td>
</tr>
<tr>
<td></td>
<td>• Does not affect carrier rate due to no mucosal immunity (Pletz et al. 2008)</td>
</tr>
</tbody>
</table>

**Table 2: Advantages and disadvantages of PCV-7 conjugate vaccine**

<table>
<thead>
<tr>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
<tbody>
<tr>
<td>• More immunogenic than 23-valent PS vaccine</td>
<td>• Limit to the amount of polysaccharide-protein linkages that can be formed</td>
</tr>
<tr>
<td>• Can be used on infants under 2 years of age</td>
<td>• Not cost effective</td>
</tr>
<tr>
<td>• Provides both, systemic and mucosal immunity</td>
<td></td>
</tr>
</tbody>
</table>

**CONCLUSION**

COVID-19 pneumonia is a specific disease with hypoxemia and is also associated with normal respiratory compliance. Hypoxemic patients have the same single etiology (SARS-CoV-2) but show different symptoms from others like normal breathing (“silent” hypoxemia) or remarkably dyspneic; quite responsive to nitric oxide or not. Polysaccharide pneumococcal vaccines have evolved over the past 20 years, using both unconjugated polysaccharides and polysaccharides conjugated to toxins to elicit a protective immune response in groups at risk for pneumococcal infection. Current CDC immunization guidelines for these vaccines have reduced the rates of pneumococcal infections within immunized communities. Vaccines against pneumonia, such as a pneumococcal vaccine, do protect against the COVID 19. The coronavirus infection has recently arisen as a pandemic and found to affect the organ systems especially, the lungs severely. So, the
researchers started the production of the vaccine against it to prevent the infection. The vaccination which is currently used to protect older people from pneumonia targets a type of bacteria called Streptococcus pneumonia is suspected to be useful for coronavirus infection also but has no clinical evidence. This review thus highlights the urge for further experimental validation on the cross-protection of the same for COVID disease.

ACKNOWLEDGMENT

Authors acknowledge the immense help received from the scholars whose articles are cited and included in references to this manuscript. The authors are also grateful to authors / editors / publishers of all those articles, journals, and books from which the literature for this article has been reviewed and discussed.

Conflict of Interest: Nil

Source of Funding: Nil

REFERENCES

Choudhary et al.: Anti-Pneumococcal Antibody and Covid 19 - A Review

and J.D. Capra [Internet]. Vol. 21, Immunology Today. 2000. p. 201. Available from: http://dx.doi.org/10.1016/s0167-5699(00)01613-3


27. Shenoy PB, Brundha MP. Awareness of polycystic ovarian disease among females of age group 18-30 years. J Pharm Sci [Internet]. 2016; Available from: http://search.proquest.com/openview/a8a09e7b2e9d2f967bf3f3e479e7018a/1?pq-origsite=gscholar&cbl=54977


33. Brundha MP. A Comparative Study- The Role of Skin and Nerve Biopsy in Hansen’s Disease.


